CMV
New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients
The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...
JUNE 6, 2023
FDA Grants New Indication for Orencia for Acute Graft-Versus-Host Disease Prophylaxis
Acute GvHD affects up to 70% of patients who receive an HSCT, particularly those coming from unrelated and ...
DECEMBER 17, 2021
FDA Approves Livtencity for Resistant Post-Transplant CMV
Although a rare disease overall, CMV is one of the most common infections experienced by both HSCT and SOT ...
NOVEMBER 24, 2021
FDA Advisory Committee Recommends Maribavir for Post-Transplant Recipients With Refractory CMV
ADAC recently recommended approval for the investigational cytomegalovirus treatment, maribavir (Takeda ...
OCTOBER 12, 2021
FDA Clears First Test for Detecting CMV in Newborns
CMV is the most common congenital infection and a leading cause of childhood cognitive deficits, hearing loss and ...
DECEMBER 11, 2018
CMV Reactivation and Rx After Allo-HCT Pose Substantial Toll
Reactivation of CMV infection and preemptive therapy to prevent progression to CMV disease in allo-HCT recipients ...
MARCH 26, 2018
FDA Approves Prevymis to Prevent CMV Among Stem Cell Transplant Patients
The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...
NOVEMBER 9, 2017
